MNA a new topical rosacea treatment

Written by on December 3, 2005 in research, Rosacea Topicals with 0 Comments

The author was kind enough to provide a copy of the article. Interesting extracts:

1-methylnicotinamide (MNA+) is one of the two major primary metabolites of nicotinamide (along with nicotinamide-N-oxide).

Although MNA+ exerts its therapeutic function through multiple mechanisms, it seems that its anti-inflammatory properties are the prime mechanism.

The reduced form, nicotinamide adenine dinucleotide (NADH), has been shown to be effective in the treatment of rosacea and contact dermatitis. The author published a paper in 2003 titled Topical application of NADH for the treatment of rosacea and contact dermatitis.

The anti-inflammatory MNA+ properties were proved by the decrease in the number of papules and pustules, intensity of erythema, and patient symptoms. The first clinical improvement could be seen in the first week, but continuation of the treatment brought greater benefit for patients. Although the study was designed as a 4-week trial, the good clinical effect resulted in some patients continuing the gel application. Follow-up at 7 months in 10 subjects confirmed not only good tolerance of prolonged gel application but also maintenance of improvement and control of recurrences. Unfortunately we did not observe any influence on telangiectasias.

Our study with this new agent of vitamin origin shows promising results, which could justify further investigation using a double blind, randomized study.

Topical application of 1-methylnicotinamide in the treatment of rosacea: a pilot study. Clinical & Experimental Dermatology, Volume 30 Issue 6 Page 632 – November 2005, Wozniacka A, Wieczorkowska M, Gebicki J, Sysa-Jedrzejowska A., Department of Dermatology, Medical University of Lodz, Poland.

Rosacea is a chronic facial dermatosis with a progressive course, which is characterized by the presence of erythema, papules, pustules, telangiectasias and sebaceous gland hyperplasia. However, the aetiology is still unknown; genetic predisposition, gastrointestinal disorders (Helicobacter pylori), infestations with Demodex folliculorum and environmental stimuli are considered to be involved in the inflammatory process. A metabolite of nicotinamide, 1-methylnicotinamide (MNA(+)), has anti-inflammatory properties, and this is the first study to test the effectiveness of this agent in treating rosacea. In total, 34 patients with rosacea were treated with a gel containing 0.25% MNA(+) as a chloride salt, twice daily for 4 weeks, after which improvement was observed in 26/34 cases. The improvement was good in 9/34 and moderate in 17/34, but no clinical effect was noted in seven subjects. In only one case was skin irritation given as the reason for treatment withdrawal. These results indicate that MNA(+) might be a useful agent for treating rosacea.

Related Articles

Read more about: research, Rosacea Topicals

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

Leave your comment here


Discover more from Rosacea Support Group

Subscribe now to keep reading and get access to the full archive.

Continue reading

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.